Oncologie

, Volume 10, Issue 6, pp 451–457 | Cite as

Recommandations pour la pratique clinique : Standards, Options : Recommandations 2008 pour la prise en charge des patientes atteintes de tumeurs épithéliales malignes de l’ovaire. Traitement médical de première ligne (rapport abrégé)

  • C. Lhommé
  • F. Planchamp
  • F. Joly
  • E. Leblanc
  • N. Albin
  • C. Alliot
  • G. Auclerc
  • L. Chaigneau
  • R. Delva
  • N. Dohollou
  • F. Goldwasser
  • C. Guillemet
  • J. -L. Misset
  • I. Ray-Coquard
  • H. Rhliouch
  • E. Touboul
  • C. Tournigand
Recommandations/Recommendations
  • 42 Downloads

Résumé

Contexte

La mise à jour de ces recommandations a été élaborée conjointement par la Fédération nationale des centres de lutte contre le cancer (FNCLCC) en partenariat avec les secteurs public, privé et l’Institut national du cancer.

Objectif

Actualiser les recommandations établies en 2003.

Méthodes

L’actualisation des Standards, Options: Recommandations (SOR) repose sur une revue et une analyse critique des données scientifiques disponibles et sur le jugement argumenté des experts au sein d’un groupe de travail représentatif des modes et lieux d’exercice et des disciplines concernées par la prise en charge des patients atteints de cancer.

Résultats

Cet article présente les recommandations SOR 2008 relatives à la place des traitements complémentaires médicaux de première ligne et de consolidation, établies à l’issue du processus d’actualisation.

Mots clés

Tumeurs épithéliales de l’ovaire Traitements médicaux de première ligne Traitements de consolidation Recommandations pour la pratique clinique 

Clinical Practice Guidelines: 2008 Update of Standards, Options: Recommendations for the management of patient with epithelial ovarian cancer — medical front-line treatment — (summary report)

Abstract

Context

The Federation of French Comprehensive Cancer Centres (FNCLCC) initiated the update of these recommendations in collaboration with the French National Cancer Institute and specialists from French public universities, general hospitals and private clinics.

Objectives

To update the recommendations established in 2003.

Methods

The guideline up-dating process is based on systematic literature review and critical appraisal by a multidisciplinary group of experts, with feedback from specialists in cancer care delivery. Consequently, Standards, Options: Recommendations are based on the best available evidence and expert agreement.

Results

This article presents the 2008 updated recommendations concerning medical first-line treatment and consolidation treatment of epithelial ovarian cancers.

Keywords

Epithelial ovarian cancer Medical first-line treatment Consolidation treatment Clinical practice guidelines 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. 1.
    AGREE, AGREE Collaboration (2003) Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: the AGREE project. Qual Saf Health Care 12: 18–23CrossRefGoogle Scholar
  2. 2.
    Alberts DS, Hannigan EV, Liu PY, et al. (2006) Randomized trial of adjuvant intraperitoneal alpha-interferon in stage III ovarian cancer patients who have no evidence of disease after primary surgery and chemotherapy: an intergroup study. Gynecol Oncol 100: 133–138PubMedCrossRefGoogle Scholar
  3. 3.
    Aravantinos G, Fountzilas G, Kosmidis P, et al. (2005) Paclitaxel plus carboplatin versus paclitaxel plus alternating carbo-platin and cisplatin for initial treatment of advanced ovarian cancer: long-term efficacy results: a Hellenic Cooperative Oncology Group (HeCOG) study. Ann Oncol 16: 1116–1122PubMedCrossRefGoogle Scholar
  4. 4.
    Armstrong DK, Bundy B, Wenzel L, et al. (2006) Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354: 34–43PubMedCrossRefGoogle Scholar
  5. 5.
    Athavale R, Godfrey K, Deane KHO (2006) The Cochrane collaboration (Protocol). Chemotherapy and/or radiotherapy after surgery fir ovarian carcinosarcoma. Cochrane Database Syst Rev: CD006246Google Scholar
  6. 6.
    Bell J, Brady MF, Young RC, et al. (2006) Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol 102: 432–439PubMedCrossRefGoogle Scholar
  7. 7.
    Berek JS, Taylor PT, Gordon A, et al. (2004) Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer. J Clin Oncol 22: 3507–3516PubMedCrossRefGoogle Scholar
  8. 8.
    Bolis G, Danese S, Tateo S, et al. (2006) Epidoxorubicin versus no treatment as consolidation therapy in advanced ovarian cancer: results from a phase II study. Int J Gynecol Cancer 16(Suppl): 174–178 (2006 January–February)CrossRefGoogle Scholar
  9. 9.
    Chen XY, Wu TX, Liu GJ (2006) The Cochrane collaboration (Protocol). Topotecan for ovarian cancer. The Cochrane database of systematic: CD005589Google Scholar
  10. 10.
    Clamp AR, Maenpaa J, Cruickshank D, et al. (2006) SCOTROC 2B: feasibility of carboplatin followed by docetaxel or docetaxel-irinotecan as first-line therapy for ovarian cancer. Br J Cancer 94: 55–61PubMedCrossRefGoogle Scholar
  11. 11.
    Covens A, Carey M, Bryson P, et al. (2004) CCOPGI Guidelines. First-line chemotherapy for postoperative patients with stage II, III or IV epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. http://www.cancercare.on.ca/index_gynecologyCancerguidelines.htm
  12. 12.
    De PS, Scambia G, Di VG, et al. (2004) Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study. J Clin Oncol 22: 2635–2642CrossRefGoogle Scholar
  13. 13.
    Du Bois A, Weber B, Rochon J, et al. (2006) Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d’investigateurs nationaux pour l’étude des cancers ovariens. J Clin Oncol 24: 1127–1135PubMedCrossRefGoogle Scholar
  14. 14.
    Elit L, Fyles A, chambers A, et al. (2004) CCOPGI Guidelines. Adjuvant care for stage I ovarian cancer. http://www.cancercare.on.ca/index_gynecology-Cancerguidelines.htm
  15. 15.
    Elit L, Oliver T, Covens A, et al. (2006) CCOPGI Guidelines. The role of intraperitoneal chemotherapy in the first-line treatment of women with stage III epithelial ovarian cancer. http://www.cancercare.on.ca/index_gynecology-Cancerguidelines.htm
  16. 16.
    Elit L, Chambers A, Fyles A, et al. (2004) Systematic review of adjuvant care for women with Stage I ovarian carcinoma. Cancer 101: 1926–1935PubMedCrossRefGoogle Scholar
  17. 17.
    Elit L, Oliver TK, Covens A, et al. (2007) Intraperitoneal chemotherapy in the first-line treatment of women with stage III epithelial ovarian cancer: a systematic review with meta-analyses. Cancer 109: 692–702PubMedCrossRefGoogle Scholar
  18. 18.
    Fervers B, Bonichon F, Demard F, et al. (1995) Méthodologie de développement des Standards, Options et Recommandations diagnostiques et thérapeutiques en cancérologie. Bull Cancer 82: 761–767PubMedGoogle Scholar
  19. 19.
    Fervers B, Hardy J, Blanc-Vincent MP, et al. (2001) SOR: project methodology. Br J Cancer 84(Suppl 2): 8–16PubMedCrossRefGoogle Scholar
  20. 20.
    Greimel ER, Bjelic-Radisic V, Pfisterer J, et al. (2006) Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin/paclitaxel versus carboplatin/paclitaxel. J Clin Oncol 24: 579–586PubMedCrossRefGoogle Scholar
  21. 21.
    Hall GD, Brown JM, Coleman RE, et al. (2004) Maintenance treatment with interferon for advanced ovarian cancer: results of the Northern and Yorkshire gynaecology group randomised phase III study. Br J Cancer 91: 621–626PubMedCrossRefGoogle Scholar
  22. 22.
    Hess LM, Ham-Hutchins M, Herzog TJ, et al. (2007) A meta-analysis of the efficacy of intraperitoneal cisplatin for the front-line treatment of ovarian cancer. Int J Gynecol Cancer 17: 561–570PubMedCrossRefGoogle Scholar
  23. 23.
    Hirte H, Vergote IB, Jeffrey JR, et al. (2006) A phase III randomized trial of BAY 12-9566 (tranomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: a National Cancer Institute of Canada Clinical Trials Group Study. Gynecol Oncol 102: 300–308PubMedCrossRefGoogle Scholar
  24. 24.
    Jaaback K, Johnson N (2006) The Cochrane collaboration (Review). Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database Syst Rev: CD005340Google Scholar
  25. 25.
    Kristensen GB, Vergote I, Stuart G, et al. (2003) First-line treatment of ovarian cancer FIGO stages IIb-IV with paclitaxel/epirubicin/carboplatin versus paclitaxel/carboplatin. Int J Gynecol Cancer 13(Suppl): 2172–2177 (2003 November–December)Google Scholar
  26. 26.
    Kyrgiou M, Salanti G, Pavlidis N, et al. (2006) Survival benefits with diverse chemotherapy regimens for ovarian cancer: meta-analysis of multiple treatments. J Natl Cancer Inst 98: 1655–1663PubMedGoogle Scholar
  27. 27.
    Minagawa Y, Kigawa J, Kanamori Y, et al. (2006) Feasibility study comparing docetaxel-cisplatin versus docetaxel-carboplatin as first-line chemotherapy for ovarian cancer. Gynecol Oncol 101: 495–498PubMedCrossRefGoogle Scholar
  28. 28.
    Mobus V, Wandt H, Frickhofen N, et al. (2007) Phase III trial of high-dose sequential chemotherapy with peripheral blood stem cell support compared with standard dose chemotherapy for first-line treatment of advanced ovarian cancer: intergroup trial of the AGO-Ovar/AIO and EBMT. J Clin Oncol 25: 418–493CrossRefGoogle Scholar
  29. 29.
    Morgan RJ Jr., Alvarez RD, Armstrong DK, et al. (2008) Ovarian cancer. Clinical practice guidelines in oncology. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp?button=l +Agree
  30. 30.
    Morrison J, Swanton A, Kehoe S (2006) The Cochrane collaboration (Protocol). Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer. Cochrane Database Syst Rev: CD005343Google Scholar
  31. 31.
    Nicoletto MO, Tumolo S, Sorio R, et al. (2007) Long-term survival in a randomized study of nonplatinum therapy versus platinum in advanced epithelial ovarian cancer. Int J Gynecol Cancer 17: 986–992PubMedCrossRefGoogle Scholar
  32. 32.
    Pfisterer J, Weber B, Reuss A, et al. (2006) Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. J Natl Cancer Inst 98: 1036–1045PubMedCrossRefGoogle Scholar
  33. 33.
    Piccart MJ, Floquet A, Scarfone G, et al. (2003) Intraperitoneal cisplatin versus no further treatment: 8-year results of EORTC 55875, a randomized phase III study in ovarian cancer patients with a pathologically complete remission after platinum-based intravenous chemotherapy. Int J Gynecol Cancer 13(Suppl): 2196–2203 (2003 November–December)Google Scholar
  34. 34.
    Ray-Coquard I, Paraiso D, Guastalla JP, et al. (2007) Intensified dose of cyclophosphamide with G-CSF support versus standard dose combined with platinum in first-line treatment of advanced ovarian cancer a randomised study from the GINECO group. Br J Cancer 97: 1200–1205PubMedCrossRefGoogle Scholar
  35. 35.
    Reed NS, Poole CJ, Coleman R, et al. (2006) A randomised comparison of treosulfan and carboplatin in patients with ovarian cancer: a study by the Scottish Gynaecological Cancer Trials Group (SGCTG). Eur J Cancer 42: 179–185PubMedCrossRefGoogle Scholar
  36. 36.
    Sorbe B, Swedish-Norgewian Ovarian Cancer Study Group (2003) Consolidation treatment of advanced (FIGO stage III) ovarian carcinoma in complete surgical remission after induction chemotherapy: a randomized, controlled, clinical trial comparing whole abdominal radiotherapy, chemotherapy, and no further treatment. Int J Gynecol Cancer 13: 278–286PubMedCrossRefGoogle Scholar
  37. 37.
    Spriggs DR, Brady MF, Vaccarello L, et al. (2007) Phase III randomized trial of intravenous cisplatin plus a 24-or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 25: 4466–4471PubMedCrossRefGoogle Scholar
  38. 38.
  39. 39.
    Vasey PA, Atkinson R, Osborne R, et al. (2006) SCOTROC 2A: carboplatin followed by docetaxel or docetaxel-gemcitabine as first-line chemotherapy for ovarian cancer. Br J Cancer 94: 62–68PubMedCrossRefGoogle Scholar
  40. 40.
    Vasey PA, Jayson GC, Gordon A, et al. (2004) Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 96: 1682–1691PubMedGoogle Scholar
  41. 41.
    Verheijen RH, Massuger LF, Benigno BB, et al. (2006) Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission. J Clin Oncol 24: 571–578PubMedCrossRefGoogle Scholar
  42. 42.
    Walker JL, Armstrong DK, Huang HQ, et al. (2006) Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study. Gynecol Oncol 100: 27–32PubMedCrossRefGoogle Scholar
  43. 43.
    Wenzel LB, Huang HQ, Armstrong DK, et al. (2007) Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 25: 437–443PubMedCrossRefGoogle Scholar
  44. 44.
    Winter-Roach B, Hooper L, Jayson G, et al. (2006) The Cochrane collaboration (Protocol). Adjuvant (postchirurgical) chemotherapy for early stage epithelial ovarian cancer. Cochrane Database Syst Rev: CD004706Google Scholar
  45. 45.
    Winter-Roach B, Hooper L, Kitchener H (2003) Systematic review of adjuvant therapy for early stage (epithelial) ovarian cancer. Int J Gynecol Cancer 13: 395–404PubMedCrossRefGoogle Scholar
  46. 46.
    Young RC, Brady MF, Nieberg RK, et al. (2003) Adjuvant treatment for early ovarian cancer: a randomized phase III trial of intraperitoneal 32P or intravenous cyclophosphamide and cisplatin: a Gynecologic Oncology Group Study. J Clin Oncol 21: 4350–4355PubMedCrossRefGoogle Scholar

Copyright information

© Springer Verlag France 2008

Authors and Affiliations

  • C. Lhommé
    • 1
  • F. Planchamp
    • 2
  • F. Joly
    • 3
  • E. Leblanc
    • 4
  • N. Albin
    • 5
  • C. Alliot
    • 6
  • G. Auclerc
    • 7
  • L. Chaigneau
    • 8
  • R. Delva
    • 9
  • N. Dohollou
    • 10
  • F. Goldwasser
    • 11
  • C. Guillemet
    • 12
  • J. -L. Misset
    • 13
  • I. Ray-Coquard
    • 14
  • H. Rhliouch
    • 15
  • E. Touboul
    • 16
  • C. Tournigand
    • 17
  1. 1.Oncologue médical (coordinatrice)institut Gustave-RoussyVillejuifFrance
  2. 2.Méthodologistechef de projet (FNCLCC)ParisFrance
  3. 3.Oncologue médicalcentre François-BaclesseCaenFrance
  4. 4.Centre Oscar-LambretLilleFrance
  5. 5.Oncologue médicalclinique MathildeRouenFrance
  6. 6.Oncologue médicalcentre hospitalier intercommunalAnnemasseFrance
  7. 7.Oncologue médicalgroupe hospitalier La Pitié-SalpêtrièreParisFrance
  8. 8.Oncologue médicalcentre hospitalier Jean-MinjozBesançonFrance
  9. 9.Oncologue médicalcentre Paul-PapinAngersFrance
  10. 10.Oncologue-radiothérapeutepolyclinique Bordeaux-Nord-AquitaineBordeauxFrance
  11. 11.Oncologue médicalhôpital CochinParisFrance
  12. 12.Oncologue médicalcentre Henri-BecquerelRouenFrance
  13. 13.Oncologue médicalhôpital Saint-LouisParisFrance
  14. 14.Oncologue médicalcentre Léon-BérardLyonFrance
  15. 15.Radiothérapeutecentre d’oncologie et de radiothérapie médicaleArrasFrance
  16. 16.Oncologue-radiothérapeutehôpital TenonParisFrance
  17. 17.Oncologue médicalhôpital Saint-AntoineParisFrance

Personalised recommendations